our Premium Content: News alerts, weekly reports and conference planners

DRUG:

ORB-011

News alerts, weekly reports and conference planners

Company:

Orionis

Drug class:

Immunomodulator, Dendritic cell activator

Related drugs:

TP53-EphA-2-CAR-DC (0)

LOAd703 (0)

DC-TC (0)

CDX-1401 (0)

personalized cellular vaccine (0)

hydroxychloroquine (7)

quaratusugene ozeplasmid (3)

HLA-matched donor mononuclear enriched leukocytes (0)

rimiducid activated rivogenlecleucel (0)

engineered donor allograft cell therapy (0)

parvovirus H-1 (0)

FT1050+FT4145 programmed mPB (0)

allodepleted T-cell immunotherapeutics (0)

TAEK-VAC-HerBy vaccine (0)

TAK-012 (0)

TST010 (0)

Undisclosed CISH inactivated TIL (0)

alpha-tocopheroloxyacetic acid (0)

dendritic cell activation therapy (0)

KRAS-EphA-2-CAR-DC (0)

CDX-301 (0)

NC410 (0)

TP53-EphA-2-CAR-DC (0)

LOAd703 (0)

DC-TC (0)

CDX-1401 (0)

personalized cellular vaccine (0)

›

ORB-011 in Patients with Advanced Solid Tumors (clinicaltrials.gov)

P1, N=36, Recruiting, Orionis Biosciences Inc | Trial completion date: Jun 2025 --> Dec 2025 | Trial primary completion date: Mar 2025 --> Aug 2025

1 month ago

Trial completion date • Trial primary completion date

ORB-011

almost2years

ORB-011 In Patients With Advanced Solid Tumors (clinicaltrials.gov)

P1, N=36, Not yet recruiting, Orionis Biosciences Inc

almost 2 years ago

New P1 trial • Metastases

ORB-011